January 23, 2026 – Abbott broadcasts monetary outcomes for the fourth quarter ended December 31, 2025.
- Fourth quarter income elevated 4.4 % on a reported foundation, 3.0 % on an natural foundation, or 3.8 % if we exclude gross sales associated to COVID-19 testing.
- GAAP diluted earnings per share for the fourth quarter of $1.01 and adjusted diluted earnings per share of $1.50, which excludes particular objects and displays development of 12 %.
- Full-year 2025 income of $44.3 billion elevated 5.7 % on a reported foundation, 5.5 % on an natural foundation, or 6.7 % when excluding gross sales associated to COVID-19 testing.
- GAAP for full yr 2025 diluted earnings per share of $3.72 and adjusted diluted earnings per share of $5.15, excluding particular objects and reflecting 10 % development.
- Abbott expects natural gross sales development between 6.5% and seven.5% for the complete yr 2026.
- Abbott expects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80, reflecting 10 % development on the midpoint.
- In November, Abbott introduced an settlement to accumulate Precise Sciences, a transfer that may place the corporate to enter and lead the fast-growing most cancers diagnostics market. Abbott continues to anticipate the transaction to shut within the second quarter of 2026.
- Abbott expanded its management in electrophysiology with two main regulatory approvals:
- In December, Abbott introduced U.S. Meals and Drug Administration (FDA) approval for its Volt™ PFA System, bringing Abbott’s first providing of pulsed subject ablation (PFA) to sufferers in america.
- In January, Abbott introduced that the corporate had obtained CE Mark approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to ship radio frequency (RF) and PFA power to deal with sufferers fighting atrial fibrillation.
Abbott expects natural gross sales development between 6.5% and seven.5% for the complete yr 2026. Abbott expects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 adjusted diluted earnings per share of $1.12 to $1.18.
Learn extra from Abbott.